NuScale Faces Earnings with Shorts Dug In and Street Turning Bearish

NuScale Power reports Q3 results on November 5 with its stock down 31% over the past month to $5.37, short interest at its highest level in over a year, and a broadening wall of analyst skepticism pressing down on the name.

The short position has become the defining feature of the stock's trading backdrop. At 32.9% of the free float, short interest rose another 0.8% over the past week and is up 16% over the past month, the bulk of that build having arrived in a single week at the end of October when positions jumped from roughly 77.5 million shares to 91 million. That level has since held firm, sitting just above 91.7 million shares as of November 3. The borrow market has partially eased since the spike. Availability in the lending pool recovered to 35.1% from a low of 18.1% on October 30, meaning roughly one share remains available for every three already lent out. That is tighter than the September readings, which ran at 55% to 65%, but well above the 52-week floor of 5.2%. Cost to borrow has drifted back down to 0.85%, about 19% below its level a week ago, confirming that the squeeze pressure evident at the end of October has partially unwound. The ORTEX short score of 69.3 ranks in the 5th percentile of the universe, flagging this as one of the more heavily shorted names on the platform. Options traders, by contrast, are not positioned defensively: the put/call ratio at 0.34 is below its 20-day average of 0.38 and near the 52-week low of 0.34, meaning call activity is dominating, a gap between options positioning and the short book that is worth noting going into the print.

The analyst community has moved firmly against the stock. In the past two weeks alone, Wedbush initiated coverage with an Underperform rating and a $5 price target, Barclays downgraded to Underweight from Equal-Weight cutting its target from $11 to $5, Citigroup trimmed its Sell target from $6.50 to $4, Truist cut its Hold target from $10 to $8, and B. Riley lowered its Buy target from $15 to $10. The consensus rating stands at Sell, with the mean price target at $10.38, well above the current price, though the gap reflects the divide between the remaining optimists and a growing bearish majority rather than any near-term upside case. The bear argument centers on regulatory risk, public opposition to nuclear, and competition from renewables eroding NuScale's addressable market. The bull case rests on the company's Small Modular Reactor technology and contracts with the Tennessee Valley Authority and ENTRA1 for 6 GW of nuclear generation. With the EV/EBITDA multiple negative and the price-to-book at 0.89, below tangible asset value, NuScale is a cash-burning pre-revenue business where traditional valuation metrics offer limited guidance. EPS momentum factor scores rank in the 14th percentile, with no improvement on either a 30-day or 90-day basis.

Institutional ownership data, reported as of September 30, shows the two largest holders added aggressively through the quarter. Van Eck Associates held 29.3 million shares, up 9.3 million on the period, representing 7.1% of shares outstanding. BlackRock added 13 million shares to reach 25.9 million, or 6.3% of the company. Mirae Asset added 10 million shares to hold 3.3% of the float. These moves are as of the last filing date and may not reflect changes since. On the activist register, Fluor Corporation holds a 13D position and remains on the register as an activist filer, though its last disclosed stake of 3.9% is down from 7.8% previously, as of April 2026. Stakes are as-last-disclosed and a holder dropping below 5% may not file again. CFO Robert Ramsey has been the primary insider trader over the past 90 days: a net sale of around $981,000 in value, with the most recent open-market activity in early October executed under a pre-arranged 10b5-1 plan, reducing the signal value of those transactions. Retail attention to the stock, measured against NuScale's own 90-day history via Wikipedia views and ORTEX page traffic, has fallen sharply, with the z-score at -2.1 as of late October.

SMR fell 5.8% over the past week, against a median decline of around 2.3% for its closest peers. Among the most correlated names, NNE dropped 7.4% and ENVX fell 12.2%, while EOSE gained 4.4% and NKLR added 8.3%, leaving NuScale broadly in the weaker half of its peer group. The last two earnings prints produced modest one-day moves of -3.1% and -0.2%, both followed by partial recoveries over five days.

What matters most on November 5 is whether management has anything new to say about the TVA partnership timeline, the regulatory path for its reactor design, and the pace of cash consumption. The short book is large and well-established, the analyst consensus is bearish, and the small call-heavy options position means the stock enters its result without a meaningful hedge cushion on the upside.